Poscale Syrup contains Posaconazole 40 mg per 5 ml, a broad-spectrum triazole antifungal that inhibits ergosterol synthesis in fungal cell membranes, effectively controlling fungal growth. Its liquid formulation provides flexible dosing and ease of administration, making it suitable for patients who cannot swallow tablets.
Clinically, Poscale Syrup is indicated for immunocompromised patients, pediatric and geriatric populations, and individuals at risk of Aspergillus or Candida infections. The syrup ensures effective prophylaxis and treatment of systemic and invasive fungal infections, especially in high-risk groups.
The formulation offers consistent absorption, precise dosing, and reliable therapeutic outcomes, making it ideal for hospitals, oncology centers, pediatric clinics, and specialty pharmacies. Oral syrup form enhances patient compliance and adherence, particularly in children and patients with swallowing difficulties.
Poscale Syrup also supports prevention of fungal proliferation, reduction of infection severity, and improved clinical outcomes. Its safe, evidence-based, and high-quality composition makes it a trusted antifungal option for managing serious systemic fungal infections in routine clinical practice.